^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

conteltinib (SY-707)

i
Other names: SY-707, CT 707, CT-707
Company:
Centaurus Biopharma, Shouyao Holdings
Drug class:
ALK inhibitor, Multi-tyrosine kinase inhibitor, IGF-1R inhibitor, FAK inhibitor, Pyk2 inhibitor
Related drugs:
almost2years
Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, first-in-human phase 1 study. (PubMed, BMC Med)
In this study, conteltinib showed manageable safety profile, favorable PK properties, and anti-tumor activity in advanced ALK-positive NSCLC patients. The recommended phase 2 dose was determined to be 600 mg QD for ALK TKI-naïve patients and 300 mg bis in die (BID) for patients who received crizotinib previously.
P1 data • Journal
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive
|
Xalkori (crizotinib) • conteltinib (SY-707)